Table 1. Patient characteristics.

UPN	Age at t-MN diagnosis (yrs)	Gender	Primary Malignancy	Treatment of primary malignancy	BM-blasts (%)	Diagnosis	Latency (months)	Karyotype	Molecular marker
1	73	F	NHL	ProMACE-Cytabom + RT	12	t-MDS	100	46,XX [25]	ASXL1 Y591*
2	62	F	APL	AIDA 2000 [17]	14	t-MDS	30	46,XX [9]/42-45, ring [13]	TP53 Y220C
3	63	M	NHL	R-CHOP, R-MICMA, autoSCT; bortezomib/lenalidomide	4	t-MDS	83	47,XY,+21 [12]	ASXL1 S689*
4	62	F	NHL	CHOP, MICMA, autoSCT, fludarabin	8.5	t-MDS	124	46,XX [12]/45,XX,-7 [6]	ASXL1 R693*
5	30	M	NHL	CODOX-M/IVAC,MICMA, autoSCT	10	t-MDS	54	46,XY,-7 [10]	absent
6	63	F	NK-AML and Breast Ca	AML-12 [18], Carboplatin, taxotere, herceptin + RT	10	t-MDS	83	46,XX [24]/46,XX,del(5)(q14q34) [1]	SF3B1K700E
7	74	F	NHL	CHOP, R-FC, chlorambucil	19	t-MDS	66	46,XX [25]	absent
8	60	F	APL	AIDA + AutoSCT	6	t-MDS	100	46,XX,-7, +21 [11]/45,XX, -7 [2]	absent
9	81	M	NHL	Chlorambucil + RT	13	t-MDS	100	Not available	IDH1 R132HSRSF2 P95H
10	74	M	NHL	R-FND, R-MICMA	4.5	t-MDS	74	46,XY [19]/44,X,-7, del(1)(p35), del(5)(q13), del(11)(q14) [6]	absent
11	37	F	HL	BEACOPP escalated	18	t-MDS	83	47-49,XX,-7, ring [10]/46,XX [1]	absent
12	50	F	HL	BEACOPP escalated	43	t-AML	18	46,XX [25]	absent
13	43	M	ALL	GMALL 05/93 [19]	7	t-MDS	32	45,XY,-7 [6]	SETBP1 G870R
14	40	F	APL	AIDA 2000 [17]	80	t-ALL	18	46,XX,t(4;11)(q21;q23)[5]	KMT2A/AFF1

Legend: NK: normal karyotype; RT: radiotherapy; ProMACE-CytaBOM: cyclophosphamide, doxorubicin, etoposide, bleomycin, vincristine, methotrexate and prednisone; AIDA: ATRA, idarubicine, mitoxantrone; R: Rituximab; CHOP: cyclophosphamide, adriblastin, vincristine, prednisone; MICMA: mitoxantrone, carboplatin, cytarabine, methylprednisolone; CODOX-M/IVAC: cyclophosphamide, doxorubicin, vincristine, methotrexate, etoposide, ifosfamide and cytarabine; FC: fludarabin, cyclophosphamide; FND: fludarabin, mitoxantrone, desametazone; AutoSCT: autologous stem cell transplantation; BEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone.